VIP and chronic obstructive pulmonary disease: When a multivariate analysis was used, NFATc3 expression/activity scores were 64% lower for COPD patients of group 3 relative to the less severe COPD patients (Group 1) and VIP mRNA lung levels were higher in those COPD patients with lower FEV/FVC ratios.